Dr. Jun He | Stem Cell Therapy | Best Researcher Award

Posted on by Pencis

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

The First Affiliated Hospital of Soochow University |  China

Author Profile

Scopus

Dr. Jun He appears to be a highly suitable candidate for the Research for Community Impact Award based on several key factors:

Extensive Professional Experience:

  • Leadership: Dr. He has been the Director of the HLA typing laboratory at the Jiangsu Institute of Hematology since 2010. This role indicates a significant leadership position within an influential research institution.
  • Long-term Commitment: Dr. He has held continuous positions of increasing responsibility at the same institution since 1985, showcasing dedication and consistent contribution to his field.

Educational Background:

  • Dr. He has a robust educational foundation in medicine, with both an M.D. and a B.S. from prestigious institutions in China (Soochow University and Suzhou Medical College).

Impactful Research:

  • Publication Record: Dr. He has published extensively in reputable peer-reviewed journals, with 33 listed publications. These papers cover critical aspects of HLA typing, stem cell transplantation, immunogenetics, and related fields, demonstrating significant contributions to medical science and community health.
  • Research Focus: His research on the genetic loci of HLA, KIRs, and their impact on transplantation outcomes is crucial for improving the success rates and safety of hematopoietic stem cell transplants, a vital area for many patients with hematological malignancies.

Professional Recognition and Membership:

  • Council Memberships: Dr. He has served as a Council Member for both the Experts Committee of the China Marrow Donor Program and The Chinese Medical Society of Organ Transplantation, indicating peer recognition and trust in his expertise.
  • International Membership: His membership in the American Society of Histocompatibility and Immunogenetics shows his engagement with the global scientific community.

Community Impact:

  • Marrow Donor Program: His long-term involvement with the China Marrow Donor Program reflects his commitment to enhancing donor registries and improving transplantation outcomes, directly benefiting patients and the broader community.
  • Training and Mentorship: As a Doctoral Supervisor, Dr. He plays a significant role in training the next generation of medical professionals and researchers, amplifying his impact on community health.

Innovative Research Contributions:

  • NGS and mNGS: His recent work using next-generation sequencing (NGS) and metagenomic NGS for pathogen identification demonstrates his engagement with cutting-edge technologies to improve clinical decision-making and patient outcomes.

In conclusion, Dr. Jun He’s distinguished career, significant research contributions, leadership roles, and dedication to community health make him a highly deserving candidate for the Research for Community Impact Award.

📊🔬Notable Publication:

    • Authors: Xu, J., Zhou, P., Liu, J., Ma, Y., He, J.
    • Journal: Infectious Diseases and Therapy
    • Year: 2023

 

    • Authors: Jiang, X., Yuan, X., Li, Y., Bao, X., He, J.
    • Journal: HLA
    • Year: 2023

 

    • Authors: Wang, L., Ji, K., Chen, L., Wu, X., He, J.
    • Journal: Frontiers in Immunology
    • Year: 2022

 

    • Authors: Zhou, S., Ma, X., Ma, C., Wu, X., Qin, S.
    • Journal: Bone Marrow Transplantation
    • Year: 2023

 

    • Authors: Cheng, Y., He, J., Zuo, B., He, Y.
    • Journal: Discover Oncology
    • Year: 2024

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Posted on by Pencis

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Beijing Tongren Hospital, Capital Medical University | China

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Shengping Hou, Ph.D., began his academic journey at Sun Yat-sen University in China, where he obtained his Ph.D. in Ocular Immunology in 2009. His doctoral research laid the foundation for his future contributions to ocular immunology, particularly focusing on the genetic aspects of ocular diseases. Following his Ph.D., Dr. Hou furthered his expertise with a postdoctoral fellowship at the University of California, San Francisco, specializing in Ocular Stem Cell Biology, which he completed in 2016.

PROFESSIONAL ENDEAVORS

Dr. Hou’s professional career commenced at The First Affiliated Hospital of Chongqing Medical University, where he served as an Associate Professor from 2009 to 2015. He was later promoted to Professor, a position he held until 2023. During his tenure, he was also a key figure at the Chongqing Key Laboratory of Ophthalmology. In 2023, Dr. Hou transitioned to Beijing Tongren Hospital, where he now serves as the Director of the Beijing Institute of Ophthalmology and continues his professorship at Capital Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOTHERAPY

Dr. Hou’s research has primarily centered on the genetic and immunological underpinnings of ocular diseases, particularly uveitis and Behcet’s disease. His work has involved extensive genetic studies, including the investigation of VKH syndrome and the role of complement component 4 copy number variants in ocular pathogenesis. His notable projects have been consistently supported by grants from the National Natural Science Foundation and other key R&D initiatives in China.

IMPACT AND INFLUENCE

Dr. Hou’s contributions have earned him significant recognition in the scientific community. He has been honored with several prestigious awards, including the First Prize for Achievement in Science and Technology from both Chongqing and the Chinese Health Ministry. His research findings have been widely disseminated through invited lectures and presentations at major international conferences, enhancing the understanding of genetic influences in ocular diseases.

ACADEMIC CITATIONS

Throughout his career, Dr. Hou has been an active member of the Chinese Ocular Immunology Society and has served as an ad hoc reviewer for several high-impact journals such as Nature Reviews Rheumatology, Advanced Science, and eBioMedicine. His work has been extensively cited by peers, reflecting the significant impact of his research on the field of ocular immunology.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Hou’s legacy in the field of ophthalmology is marked by his dedication to uncovering the genetic mechanisms underlying ocular diseases. As the Director of the Beijing Institute of Ophthalmology, he continues to lead groundbreaking research and mentor the next generation of scientists. His future contributions are poised to further advance the understanding and treatment of ocular conditions, solidifying his status as a leading figure in ophthalmic research.

NOTABLE PUBLICATION:

Citation: 36         Year: 2023

Citation: 01        Year: 2023

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023